Senores Pharmaceuticals Plans ₹43 Crore Expansion in US and India, Adds Prefilled Syringe Line
Published
Senores Pharmaceuticals has announced a capacity expansion plan worth ₹43 crore across its facilities in the United States and India. The company plans to complete the project by the end of March 2027. The expansion is an important step for the company as it grows its production in both countries.
A major part of the plan is to increase the company's output capacity. Production capacity is expected to rise from 1.2 billion units a year to 2.0 billion units a year. The estimated cost of this increase is ₹18 crore. This will allow the company to produce a much larger number of products each year to meet growing demand.
As part of the expansion, Senores Pharmaceuticals will also add a new prefilled syringe line. A prefilled syringe is a medical device that comes already filled with a set dose of medicine, so it is ready to use without measuring. These products are widely used in hospitals and clinics, and they are often preferred for their convenience and accuracy. The new line will strengthen the company's range of products.
The project shows the company's plans to grow its manufacturing base in both the US and India over the next few years. Readers can follow further updates as the work moves forward toward the March 2027 deadline.
Sources: eHealth Magazine
More India news
- Cheaper Batteries Make Solar and Wind the Lowest-Cost Power Source in India, Says BNEF
- Why Money Flowing Out of India Is Drawing Attention
- Qualcomm Layoffs: What Severance Will Former Employees in India Receive?
- Suriya's Cop Comedy 'Scene' Earns Rs 111 Crore in Five Days at the Box Office
- Ajay Devgn's Drishyam 3: The Conclusion Passes Rs 588 Crore Worldwide After 40 Days
- Ramayana: Part 1 Continues Strong Box Office Run with Rs 440 Crore Collection
- Government Uses Online Marketplace to Buy Farm and Allied Sector Goods
- World Bank Estimates Extreme Poverty in India at 2.6 Per Cent, Sparking Debate